drugset
drugset / Trial / NCT05288660

A Study of a Single Dose of ALXN1210 in Healthy Participants

NCT05288660 ↗

Phase 1 Completed 14 enrolled Alexion Pharmaceuticals, Inc.
RandomizedSequentialTriple-blindBasic science

Summary

This study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of ALXN1210 in healthy participants, as assessed by electrocardiograms, physical examination, vital signs, laboratory analysis, and assessment of adverse events (AEs).

Timeline

Start
2014-08-27
Primary completion
2015-03-13
Completion
2015-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravulizumab Monoclonal antibody 200 mg Intravenous
Subject Ravulizumab Monoclonal antibody 400 mg Intravenous

Indications

No indication recorded.